Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 10Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Leukemia, Myeloid, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Hodgkin Disease 5Leukemia, Biphenotypic, Acute 4Hematologic Neoplasms 4Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Sarcoma 2Rhabdomyosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Ewing 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Temozolomide 7Vincristine 6Cyclophosphamide 5fludarabine 3Irinotecan 3pegfilgrastim 2irinotecan sucrosofate 2Zoledronic Acid 2Vinorelbine 2Filgrastim 2Dactinomycin 2talazoparib 1silmitasertib 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pazopanib 1liposomal doxorubicin 1fludarabine phosphate 1cabozantinib 1atezolizumab 1amino-acid, glucose, and electrolyte solution 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Radiotherapy 1Mesna 1Melphalan 1Influenza Vaccines 1Indocyanine Green 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Rhabdomyosarcoma × Filgrastim × Clear all
NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

St. Jude Children's Research Hospital

Phase 2 Recruiting
135 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡